Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

Albireo Pharma logo

About Albireo Pharma Stock (NASDAQ:ALBO)

Advanced Chart

Key Stats

Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALBO Stock News Headlines

Prospect Park II in Fort Lauderdale
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
ALBO Historical Data
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
See More Headlines

ALBO Stock Analysis - Frequently Asked Questions

Albireo Pharma, Inc. (NASDAQ:ALBO) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative trailing twelve-month return on equity of 97.13% and a negative net margin of 228.51%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN).

Company Calendar

Last Earnings
11/04/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALBO
CIK
1322505
Employees
130
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
($6.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-228.51%
Pretax Margin
-235.11%
Return on Equity
-97.13%
Return on Assets
-46.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.32
Quick Ratio
6.23

Sales & Book Value

Annual Sales
$40.58 million
Price / Sales
22.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.11 per share
Price / Book
4.85

Miscellaneous

Outstanding Shares
20,700,000
Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ALBO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners